Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges by K. Sandy Pang
Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges by K. Sandy Pang
Springer; 2010 edition | April 1, 2010 | English | ISBN: 1441908390 | 742 pages | PDF | 19 MB
Springer; 2010 edition | April 1, 2010 | English | ISBN: 1441908390 | 742 pages | PDF | 19 MB
Germination of the thought of "Enzymatic- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges" Proceedings came about as part of the annual meeting of The American Association of Pharmaceutical Scientists (AAPS) that was held in San Diego in November of 2007. The attendance of workshop by more than 250 pharmaceutical scientists reflected the increased interest in the area of drug-drug interactions (DDIs), the greater focus of PhRMA, academia, and regulatory agencies, and the rapid pace of growth in knowledge. One of the aims of the workshop was to address the progress made in quantitatively predicting enzyme- and transporter-based DDIs as well as highlighted areas where such predictions are poor or areas that remain challenging for the future. Because of the serious clinical implications, initiatives have arisen from the FDA (http://www.fda.gov/cber/gdlns/interactstud.htm) to highlight the importance of enzyme- and transporter-based DDIs.